LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that AstraZeneca has nominated the first product candidate under its siRNA (short interfering RNA) collaboration and will pay Silence a […]
Other News
LivaNova Reports First-Quarter 2023 Results
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights1 First-quarter revenue of $263.4 million increased 9.7 percent on a reported basis and increased 12.7 percent on a constant-currency […]
Adagio Medical Announces Completion of Enrollment in Cryocure-VT Trial, Maps the Pathway to CE-Mark of vCLAS™ VT Ablation Catheter
LAGUNA HILLS, Calif., May 3, 2023 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the completion of enrollment in its Cryocure-VT trial (NCT # 04893317) of ultra-low temperature cryoablation (ULTC) for the treatment of monomorphic ventricular tachycardias. 60 patients […]
Occlutech Year-end Report 2022 – Significant Uptick in Sales Growth as Transformation Processes are Reaching an End
SCHAFFHAUSEN, CH / ACCESSWIRE / May 3, 2023 / Occlutech Holding AG Occlutech Holding AG (Occlutech) is a leading specialist provider of minimally invasive structural heart implants. The company sells and markets its products in around 85 countries and the global addressable market for congenital and structural heart devices provides a […]
LeMaitre Q1 2023 Financial Results
BURLINGTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) — LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q1 2023 Financial Results Sales $47.1mm, +19% (+22% organic) vs. Q1 2022 Op. income $7.9mm, -1% Op. margin 17% […]
Magenta Medical Closes $55M Funding Round Led by OrbiMed
Funding will further Magenta’s clinical programs in support of FDA approval for world’s smallest heart pump KADIMA, Israel, May 3, 2023 /PRNewswire/ — Magenta Medical, developer of the world’s smallest heart pump, announced today a $55M financing round led by global healthcare investment manager OrbiMed, with participation from existing investors New Enterprise Associates (NEA), Pitango VC, […]
Aktiia’s Continual Blood Pressure Solution Shows Comparable Results to ABPM
NEUCHÂTEL, Switzerland, May 3, 2023 /PRNewswire/ — Aktiia, a health tech startup transforming hypertension care, has announced promising results from a preliminary study comparing their cuff-less and continual blood pressure monitor with traditional ambulatory blood pressure monitors (ABPM). The study included 52 patients enrolled in a 12-week cardiac rehabilitation program and found that […]
AliveCor’s KardiaMobile Card Honored by Fast Company’s 2023 World Changing Ideas Awards and the 2023 MedTech Breakthrough Awards
KardiaMobile Card recognized for its contributions to digital health MOUNTAIN VIEW, Calif., May 3, 2023 /PRNewswire/ — AliveCor, the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced that KardiaMobile Card, the world’s thinnest and lightest personal ECG, has been honored on Fast Company’s 2023 World Changing Ideas list in the Health category and awarded the 2023 […]
Ionis reports first quarter 2023 financial results
QALSODY approved for SOD1-ALS; MAA under review in EU Reported positive Phase 3 eplontersen ATTRv-PN data; December 22, 2023 PDUFA date On track to achieve 2023 financial guidance CARLSBAD, Calif., May 3, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”), today reported financial results for the first quarter of 2023. Financial results are summarized below: […]
Penumbra, Inc. Reports First Quarter 2023 Financial Results
ALAMEDA, Calif., May 2, 2023 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2023. Revenue of $241.4 million in the first quarter of 2023, an increase of 18.4%, or 19.7% in constant currency1, compared to the first quarter of […]